Bevacizumab biosimilar(PharmAbcine)

贝伐珠单抗生物类似药（PharmAbcine）

Report date: 2022/03/16 15:06:02

Base Information

Drug NameBevacizumab biosimilar(PharmAbcine)
Drug Alias NamePMC-901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPharmabcine
China Registration ClassN/A

Develop Information

Active CompaniesPharmabcine
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A